Remplir's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Remplir. Showing past 6 months and next 12 months · 2 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Remplir | Orthocell | Regenerative Biologic | Approved | 0 | ||||
| Pre-Incision Peripheral Nerve Blocks for Lower Extremity Fracture Surgery in Older Adults | University of Maryland, Baltimore | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations. | Neuraptive Therapeutics Inc. | — | Phase 3 | — | — | — | — | — |
| NAC-REPAIR for Post-surgical Pain | University of Arizona | — | Phase 2 | — | — | — | — | — |
| Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion) | Major Extremity Trauma Research Consortium | — | Phase 2 | — | — | — | — | — |